Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - Targeted Medical Pharma, Inc. | ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - Targeted Medical Pharma, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 10, 2014
TARGETED MEDICAL PHARMA, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-53071 | 20-5863618 | ||
| (State
or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
2980 Beverly Glen Circle, Suite 301 Los Angeles, California |
90077 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (310) 474-9809
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 4, 2014, Targeted Medical Pharma, Inc. (the “Company”) appointed Dr. Thomas Wenkart to serve as a director on the Company’s Board of Directors. Dr. Wenkart will also serve as the Chairman of the Company’s Compensation Committee. There were no arrangements or understandings pursuant to which Dr. Wenkart was appointed as a director of the Company. On December 23, 2013, Dr. Wenkart purchased 416,667 shares of the Company’s common stock, par value $0.001 per share, from the Company for a total purchase price of $250,000.
Item 8.01 Other Events.
On March 10, 2014, the Company issued a press release announcing the appointment of Dr. Wenkart as a director of the Company. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are filed with this Current Report on Form 8-K:
| Exhibit No. | Description | |
| 99.1 | Press Release dated March 10, 2014 | |
| 99.2 | Dr. Tom Wenkart - Bio |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 11, 2014
| TARGETED MEDICAL PHARMA, INC. | ||
| By: | /s/ William B. Horne | |
| Name: | William B. Horne | |
| Title: | Chief Financial Officer | |